CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00459940
NCT00459940N/ACompleted
CompareCT.gov

"Can Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?"

University of Aarhus·interventional·Posted Apr 13, 2007·Updated Apr 13, 2007

In Brief

A clinical study evaluating Pioglitazone for Growth Hormone Deficiency. Completed, across 1 site.

Detailed Summary

In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growth hormone-replaced adults with growth hormone deficiency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Hormone Deficiency
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2007
Enrollment StartSep 1, 2004
Study CompletionMar 1, 2006
TodayJul 2, 2026
Posted 19.2 years ago

Interventions

Pioglitazonedrug